Boundless Bio Announces Departure of Chief Financial Officer
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) — Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Jami Rubin has stepped down from her role as Chief Financial Officer (CFO) for personal reasons. Boundless Bio does […]